PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells

Regulatory Peptides

Volumn 109, Issue 1-3, 2002, Pages 115-125

  Le, Sang V ^a,b   Yamaguchi, Dean J ^a,b   McArdle, Craig A ^c   Tachiki, Ken ^a,b   Pisegna, Joseph R ^a,b   Germano, Patrizia ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Colon cancer growth; HCT8 cells; Pituitary adenylate cyclase activating polypeptide; Pituitary adenylate cyclase activating polypeptide type 1 receptor

Indexed keywords

ADENYLATE CYCLASE; CALCIUM ION; CYCLIC AMP; FAS ANTIGEN; FLUORESCENT DYE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; POLYCLONAL ANTIBODY;

ARTICLE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLON TUMOR; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; APOPTOSIS; BACTERIAL PROTEINS; CALCIUM; CELL DIVISION; COLONIC NEOPLASMS; DOWN-REGULATION; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICROSCOPY, CONFOCAL; NEUROPEPTIDES; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, PITUITARY HORMONE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0037111406     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00194-5     Document Type: Article

References (49)

1. Miyata A., Arimura A., Dahl R.R., Uehara A., Jiang L., Culler M.D.et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164:1989;567-574.
2. Miyata A., Jiang L., Dahl R.R., Kitada C., Kubo K., Fujino M.et al. Isolation of a neropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP-38). Biochem. Biophys. Res. Commun. 170:1990;643-648.
3. Said S.I., Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science. 69:1970;1217-1218.
4. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R.et al. International Union of Pharmacology: XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50(2):1998;265-270.
5. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52(2):2000;269-324.
6. Cauvin A., Buscail L., Gourlet P., De Neef P., Gossen D., Arimura A.et al. The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK. Peptides. 11(4):1990;773-777.
7. Zia F., Fagarasan M., Bitar K., Coy D.H., Pisegna J.R., Wank S.A.et al. Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. Cancer Res. 55(21):1995;4886-4891.
8. Moody T.W., Zia F., Makheja A. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides. 14(2):1993;241-246.
9. Buscail L., Cambillau C., Seva C., Scemama J.L., De Neef P., Robberecht P.et al. Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating peptide. Gastroenterology. 103(3):1992;1002-1008.
10. Leyton J., Gozes Y., Pisegna J.R., Coy D., Purdom S., Casibang M.et al. PACAP (6-38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Res. Treat. 56:1999;177-186.
11. Zeng N., Kang T., Wong H., Walsh J.H., Sachs G.A., Pisegna J.R. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J. Clin. Invest. 104:1999;1383-1391.
12. Pisegna J.R., Leyton J., Coelho T., Hida T., Jakolew S., Birrer S.et al. Differential activation of immediate-early gene expression by four splice variants of the human pituitary activating polypeptide receptor: evidence for activation by PACAP hybrid and the phospholipase C inhibitor U73122. Life Sci. 61(6):1997;631-639.
13. Lu N., Zhou R., DiCicco-Bloom E. Opposing mitogenic regulation by PACAP in sympathetic and cerebral cortical precursors correlates with differential expression of PACAP receptor (PAC1-R) isoforms. J. Neurosci. Res. 53:1998;651-662.
14. Lu N., DiCicco-Bloom E. Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3357-3362.
15. Suh J., Lu N., Nicot A., Tatsuno I., DiCicco-Bloom E. PACAP is an anti-mitogenic signal in developing cerebral cortex. Nat. Neurosci. 4(2):2001;123-124.
16. Gonzalez B.J., Basille M., Mei Y.A., Vaudry D., Fournier A., Cazin L.et al. Ontogeny of PACAP and PACAP receptors in the rat brain: role of PACAP in the cerebellum during development. Ann. N.Y. Acad. Sci. 805:1996;302-314.
17. Journot L., Villalba M., Boachaert J. PACAP-38 protects cerebellar granule cells from apoptosis. Ann. N.Y. Acad. Sci. 865:1998;100-110.
18. Vaudry D., Gonzalez B.J., Basille M., Fournier A., Vaudry H. Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. Proc. Natl. Acad. Sci. 96:1999;9415-9420.
19. Zeng N., Athmann C., Kang T., Lyu R.M., Walsh J.H., Ohning G.V.et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J. Clin. Invest. 104(10):1999;1383-1391.
20. Lauffer J.M., Modlin I.M., Hinoue T., Kidd M., Zhang T., Schmid S.W.et al. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats. Gastroenterology. 116(3):1999;623-635.
21. Pisegna J.R., Ohning G.V., Athmann C., Zeng N., Walsh J.H., Sachs G. Role of PACAP1 receptor in regulation of ECL cells and gastric acid secretion by pituitary adenylate cyclase activating peptide. Ann. N.Y. Acad. Sci. 921:2000;233-241.
22. Miampamba M., Germano P.M., Arli S., Wong H.H., Scott D., Tache Y.et al. Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type I receptor in the rat gastric and colonic myenteric neurons. Regul. Pept. 105(3):2002 (May 30);145-154.
23. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A.et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer. 57(3):1994 (May 1);371-377.
24. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D.et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2(12):1996 (Dec.);1361-1366.
25. French L.E., Tschoop J. Defective death receptor signaling as a cause of tumor immune escape. Semin. Cancer Biol. 12(1):2002;51-55.
26. Nagata S., Golstein P. The Fas death factor. Science. 267(5203):1995;1449-1456.
27. Cleveland J.L., Ihle J.N. Contenders in FasL/TNF death signaling. Cell. 81(4):1995;479-482.
28. Singer G.G., Abbas A.K. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1(5):1994 (Aug.);365-371.
29. Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A.et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181(1):1995;71-77.
30. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F.et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373(6513):1995;441-444.
31. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373(6513):1995 (Feb. 2);438-441.
32. Pisegna J.R., Wank S.A. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J. Biol. Chem. 271:1996;17267-17274.
33. Germano P.M., Stalter J., Le S.V., Wu M., Yamaguchi D.J., Scott D.et al. Characterization of the pharmacology, signal transduction and internalization of the fluorescent PACAP ligand, fluor-PACAP, on NIH/3T3 cells expressing PAC1. Peptides. 22(6):2001;861-866.
34. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:1974;541-548.
35. McArdle C.A., Schomerus E., Groener I., Poch A. Estradiol regulates gonadotropin-releasing hormone receptor number, growth and inositol phosphate production in T3-1, gonadotrope-derived cell line. Mol. Cell. Neurosci. 3:1992;124-132.
36. 2+ indicator with greatly improved fluorescence properties. J. Biol. Chem. 260:1995;3440-3450.
37. Gottschall P.E., Tatsuno I., Miyata A., Arimura A. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase activating polypeptide (PACAP): characterization and molecular identification. Endocrinology. 127:1990;272-277.
38. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H.et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond.). 365:1993;170-175.
39. Pisegna J.R., Wank S.A. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6345-6349.
40. Svoboda M., Tastenoy M., Ciccarelli E., Stievenart M., Christopher J. Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor. Biochem. Biophys. Res. Commun. 195:1993;881-888.
41. Lyu R., Germano P.M., Choi J.K., Le S.V., Pisegna J.R. Identification of an essential amino acid motif within the C-terminus of the pituitary adenylate cyclase-activating polypeptide type 1 receptor that is critical for signal truncation but not for receptor internalization. J. Biol. Chem. 275(46):2000;36134-36142.
42. Moody T.W., Leyton J., Casibang M., Pisegna J.R., Jensen R.T. PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul. Pept. 2002;. [in press].
43. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M.et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66(2):1991;233-243.
44. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75(6):1993;1169-1178.
45. Lynch D.H., Ramsdell F., Alderson M.R. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today. 16(12):1995;569-574.
46. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16(1):1995;39-43.
47. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1996;1075-1082.
48. Germano P., Wu M., Yamaguchi D.J., Tachiki K., Pisegna J.R. PACAP hormone effects on PAC1-posititve Jurkat cells. Regul. Pept. 102:2001;55. [Abstract].
49. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev T.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17:1999;331-367.